PCM
FOLD

Pentwater Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Pentwater Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202M Buy
14,000,000
+2,500,000
+22% +$35.8M 1.05% 22
2025
Q4 		$164M Buy
+11,500,000
New +$113M 0.86% 21

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Pentwater Capital Management's FOLD Position: Q1 2026 in Review

Pentwater Capital Management increased its Amicus Therapeutics (FOLD) stake by 22% in Q1 2026, buying an estimated $35.8M and bringing the position to 14,000,000 shares worth $202M. The position accounts for 1.05% of the portfolio, ranked #22.

Pentwater Capital Management first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Pentwater Capital Management held 14,000,000 shares of Amicus Therapeutics worth $202M as of Q1 2026.
  • Pentwater Capital Management bought 2,500,000 Amicus Therapeutics shares in Q1 2026, an estimated $35.8M.
  • Amicus Therapeutics made up 1.05% of Pentwater Capital Management's portfolio in Q1 2026, its #22 holding.
  • Pentwater Capital Management first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Pentwater Capital Management's 13F filing for Q1 2026, filed 15 May 2026.